Last updated on November 2018

Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT)


Brief description of study

The purpose of this research is to determine if an investigational new drug solution called Prismocitrate 18 lengthens extracorporeal circuit life in patients treated with continuous renal replacement therapy (CRRT). Patients who receive CRRT treatment with Prismocitrate 18 as the anticoagulant will be compared to patients who receive CRRT treatment with no anticoagulation.

Clinical Study Identifier: NCT02860130

Contact Investigators or Research Sites near you

Start Over

Eric Judd, MD

University of Alabama at Birmingham
Birmingham, AL United States

Bijin Thajudeen, MD

University of Arizona
Tucson, AZ United States

Baxter Clinical Trials Disclosure Call ...

UCLA
Los Angeles, CA United States

Justin Belcher, MD

Yale University School of Medicine
New Haven, CT United States

Michael Connor, MD

Emory University
Atlanta, GA United States

Cybele Ghossein-Hoseen, MD

Northwestern University
Chicago, IL United States

Jason Stubbs, MD

University of Kansas Medical Center
Kansas City, KS United States

Javier Neyra, MD

University of Kentucky
Lexington, KY United States

Daniel Herr, MD

University of Maryland Medical Center
Baltimore, MD United States

Bradley Denker, MD

Beth Israel Deaconess (Harvard)
Boston, MA United States

Baxter Clinical Trials Disclosure Call ...

University of Mississippi Medical Center
Jackson, MS United States

Baxter Clinical Trials Disclosure Call ...

Cleveland Clinic
Cleveland, OH United States

Sean Bagshaw, MD

University of Alberta Hospital
Edmonton, AB Canada

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.